When are the big time biotech press going to start buzzing on the imminent top-line data release of BETonMACE? Crickets right now. CVOT trials usually generate a lot of buzz, especially as they approach their event total and near top-line data release. What is it going to take to get these biotech press to start writing on Resverlogix, apabetalone and BETonMACE? I find it hard to believe that there won't be buzz in the month or two leading up to top-line data announcement.

Perhaps an end of 2018 announcement that 250 events (not all adjudicated yet) have occurred and that BETonMACE last patient dosing has been completed will be the catalyst to getting more biotech press attention? Then, for the 1-2 months leading up to Q1 2019 top-line data release, during which the adjudication process in completed, maybe we'll see the biotech press buzzing.

BearDownAZ